MAYNE PHARMA GROUP LIMITED — M&A Activity 2025

Oct 15, 2025

==> picture [117 x 45] intentionally omitted <==

ASX Announcement

NOTICE OF HEARING TO APPROVE THE PROPOSED SCHEME OF ARRANGEMENT

16 October 2025, Adelaide, Australia: Mayne Pharma Group Limited ACN 115 832 963 (ASX:MYX) ( Mayne Pharma ) refers to its announcement on 15 May 2025 in relation to:

• the proposed scheme of arrangement under which it is proposed that Cosette Australia BidCo Pty Ltd ACN 685 921 126 will acquire 100% of the shares in Mayne Pharma by way of a scheme of arrangement ( Scheme ), subject to all applicable conditions being satisfied or waived (as applicable); and

• the orders made by the Supreme Court of New South Wales that Mayne Pharma convene a meeting of Mayne Pharma shareholders ( Scheme Meeting ) to consider and vote on the resolution to approve the Scheme ( Scheme Resolution ) and approving the distribution of an explanatory statement providing information about the Scheme and the Notice of Scheme Meeting ( Scheme Booklet ) to Mayne Pharma shareholders.

As previously announced to the ASX, Mayne Pharma shareholders approved the Scheme by the requisite majorities at the Scheme Meeting held on 18 June 2025. The Court hearing to approve the Scheme ( Second Court Hearing ) is scheduled to take place at 2:00pm (AEDT) on Wednesday, 22 October 2025 at the Supreme Court of New South Wales, 184 Phillip St, Sydney NSW 2000.

Any Mayne Pharma shareholder has a right to appear and be heard at the Second Court Hearing and may oppose the approval of the Scheme.

If you wish to oppose the approval of the Scheme, you must file with the Court and serve on Mayne Pharma a notice of appearance in the prescribed form, together with any affidavit on which you wish to rely at the hearing. The notice of appearance and affidavit must be served on Mayne Pharma at its address for service at least 1 day before the Second Court Hearing.

Mayne Pharma's address for service is c/- Gilbert+ Tobin, Level 35, Tower Two, International Towers, 200 Barangaroo Avenue, Sydney NSW 2000 (Attention: Alexandra Whitby).

- ENDS -

Authorised for release to the ASX by the Board Chair

For further information contact:

Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com

==> picture [227 x 54] intentionally omitted <==

==> picture [126 x 130] intentionally omitted <==

==> picture [128 x 46] intentionally omitted <==

ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women’s health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

==> picture [125 x 129] intentionally omitted <==

Page 2